Blood-Based Biomarkers in Sarcoma: A ‘Multi-Omics’ Approach

Overview

About this study

The purpose of this research is to determine whether circulating tumor DNA, RNA or proteins can be detected in the blood of patients with sarcoma. We are also interested in learning if these levels change over time while receiving chemotherapy. Patients with advanced sarcoma who will receive chemotherapy will be asked to participate. Study participation involves blood-draws of approximately 4 tablespoons of blood at each of 4 separate time-points as well as access to archived tumor tissue, or fresh tumor tissue at the time of clinically indicated biopsy or surgery.  We hypothesize that circulating tumor DNA, RNA and/or proteins will be detectable in blood of sarcoma patients, and change in measured values over time will correlate with disease response or progression on therapy.

Pediatric patients weighing at least 10 kg will be considered for enrollment. For pediatric participants, 1.5 tablespoons of blood at each of 4 separate time-points will be collected. All blood collection will coincide with clinical lab draws. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult and pediatric patients will be considered eligible for accrual.
  • Pediatric patients (Age < 18 years) must weigh ≥ 10 kg for consideration.
  • Diagnosis of previously untreated or progressive sarcoma who will receive systemic chemotherapy.
  • Willing and able to provide written informed consent and age appropriate assent for minors.
  • Planned clinical biopsy/surgery or available archived tumor tissue.

Exclusion Criteria: 

  • Pediatric sarcoma patients weighing < 10 kg.
  • Unable/unwilling to provide written informed consent.

Eligibility last updated 1/13/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Brittany Siontis, M.D.

Open for enrollment

Contact information:

Brittany Siontis M.D.

(507) 293-0585

Siontis.Brittany@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20502720

Mayo Clinic Footer